CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Selective 5-HT1B/1D serotonin receptor agonist
Updated · Methodology
Mechanism
Rizatriptan binds with high affinity to serotonin receptors in intracranial vessels and the trigeminal nerve, and stimulating these receptors can constrict intracranial vessels. Ergotamine, an ergot alkaloid, also constricts arteries. Vasospasm after ergot drugs can be prolonged, and ergotamine itself can cause myocardial ischaemia even in people with no known heart disease. According to the Spanish rizatriptan summary of product characteristics (SmPC), the effects of the two drugs add up. Together they raise the risk of coronary artery constriction and of rises in blood pressure. In a study of 16 healthy men, oral rizatriptan with injected ergotamine caused no extra vasospasm, but the effects may in theory add up.
Symptoms
After rizatriptan, people may have passing chest tightness and pain, sometimes intense and spreading to the throat, palpitations, a fast pulse, flushing and a rise in blood pressure. Myocardial ischaemia and infarction have occurred mostly in people with risk factors for coronary artery disease. In rare cases, triptans have caused hypertensive crisis with acute organ damage and life-threatening arrhythmias within hours of a dose. Spasm of other arteries causes peripheral vascular ischaemia and ischaemic colitis with abdominal pain and bloody diarrhoea. Vasospasm from ergotamine starts with numbness and tingling in the fingers and toes, headache and pain over the heart. In ergotism the limbs hurt and turn blue and their pulses disappear.
Management
The rizatriptan documents of the Spanish Agency of Medicines and Medical Devices (AEMPS) and the US Food and Drug Administration (FDA) contraindicate the combination. So does the Spanish summary of product characteristics (SmPC) for ergotamine with caffeine, which contraindicates all triptans and names rizatriptan (AEMPS). Take rizatriptan no sooner than 24 hours after an ergotamine product. After rizatriptan, the Spanish SmPC advises waiting at least 6 hours before ergotamine or other ergot drugs, while the US label requires the same 24 hours (rizatriptan SmPC, AEMPS, and label, FDA). If ergotamine has not been enough for an attack, do not use a triptan as an add-on for that attack (ergotamine with caffeine SmPC, AEMPS). Rizatriptan is contraindicated in moderately severe or severe hypertension and in untreated mild hypertension (rizatriptan SmPC, AEMPS). Ergotamine is contraindicated in poorly controlled hypertension (ergotamine with caffeine SmPC, AEMPS). If chest tightness and pain after rizatriptan suggest cardiac ischaemia, give no further doses and evaluate the heart (rizatriptan SmPC, AEMPS). If numbness and tingling in the fingers, pain over the heart or other signs of vasospasm appear, stop ergotamine at once. Treat severe vasospasm with an intravenous peripheral vasodilator, and coronary constriction with appropriate treatment such as nitroglycerin (ergotamine with caffeine SmPC, AEMPS). Stop rizatriptan if arrhythmias occur. If abdominal pain with bloody diarrhoea or signs of limb ischaemia appear, rule out vasospasm before the next rizatriptan dose (rizatriptan label, FDA). Taking ergotamine, triptans or both on 10 or more days a month can make attacks more frequent, even to the point of daily migraine-like headaches. The overused drugs may then need to be withdrawn (rizatriptan label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ergotamina/cafeína (nº registro 17558), sección 4.3 (2025)– AEMPS, CIMA, nº registro 17558 (Cafergot 1 mg/100 mg comprimidos, Amdipharm), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Rizatriptán (nº registro 62289), sección 4.3 (2024)– AEMPS, CIMA, nº registro 62289 (Maxalt 10 mg comprimidos, Organon Salud), revisión 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: MAXALT (rizatriptan benzoate) prescribing information (2026)– FDA, DailyMed setid 007b4644-e0e7-4863-9ae3-fe09676b3f5f (Organon), revisión 01/2026 (versión 4), secciones 4, 5.2, 5.5, 5.6, 5.8 y 7.2